Current status of anticoagulation therapy for elderly atrial fibrillation patients in Japan - From Hokuriku atrial fibrillation trial

Circulation Journal

Volumn 72, Issue 12, 2008, Pages 2058-2061

  Furusho, Hiroshi ^a   Takamura, Masayuki ^a   Takata, Shigeo ^b   Sakagami, Satoru ^c   Hirazawa, Motoaki ^a   Kato, Takeshi ^a   Murai, Hisayoshi ^a   Okajima, Masaki ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Kanazawa Municipal Hospital   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

Author keywords

Aging; Anticoagulation; Atrial fibrillation; Japanese

Indexed keywords

ACETYLSALICYLIC ACID; DILAZEP; LIMAPROST; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG USE; FEMALE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; REGISTER; SCORING SYSTEM; THROMBOEMBOLISM;

AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; JAPAN; MALE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RISK ASSESSMENT; THROMBOEMBOLISM; WARFARIN;

EID: 56849109349     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0290     Document Type: Article

References (17)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
2. Hashiba K. Rounensha no Fuseimyaku. Nichirouishi 1989; 26: 101-110 (in Japanese).
3. The Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: A systematic review. Neurology 2007; 69: 546-554.
4. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
5. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2006; 114: e257-e354.
6. Ogawa S, Aizawa Y, Atarashi H, Inoue H, Okumura K, Kamakura S, et al. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2006). Available at: http://www.j-circ.or.jp/guideline/index.htm (in Japanese).
7. Research Group for Antiarrhythmic Drug Therapy. Survey of atrial fibrillation and thromboembolism in the elderly: A multicenter cooperative study. J Cardiol 1999; 33: 27-35 (in Japanese with English abstract).
8. Tomita F, Kohya T, Sakurai M, Kaji T, Yokoshiki H, Sato M, et al. Prevalence and clinical characteristics of patients with atrial fibrillation: Analysis of 20,000 cases in Japan. Jpn Circ J 2000; 64: 653-658.
9. Inoue H, Nozawa T, Okumura K, Iwasa A, Lee JD, Shimizu A, et al. Attitudes of Japanese cardiologists toward anticoagulation for nonvalvular atrial fibrillation and reasons for its underuse. Circ J 2004; 68: 417-421.
10. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
11. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006; 367: 1903-1912.
12. Sam C, Massaro JM, D'Agostino RB Sr, Levy D, Lambert JW, Wolf PA, et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol 2004; 94: 947-951.
13. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37: 1075-1080.
14. Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006; 70: 651-656.
15. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685-2692.
16. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-934.
17. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007; 370: 493-503.